Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 April;61(2) > Minerva Cardioangiologica 2013 April;61(2):125-34

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

  INTERVENTIONAL INNOVATION NOVEL THERAPIES AND THE BEST NEW DEVICE CONCEPT FOR 2013


Minerva Cardioangiologica 2013 April;61(2):125-34

language: English

Left atrial appendage closure devices. Their role in 2013

Mangner N. 1, Sandri M. 1, Lurz P. 1, Dähnert I. 2, Schuler G. 1, Möbius-Winkler S. 3

1 Heart Center Department of Internal Medicine/Cardiology University of Leipzig, Leipzig, Germany;
2 Heart Center Department of Pediatric Cardiology University of Leipzig, Leipzig, Germany;
3 Asklepios Clinic Weissenfels Department of Cardiology, Weissenfels, Germany


PDF  


Stroke prevention is the major goal in treating patients with atrial fibrillation. Warfarin therapy, if used appropriately, is highly effective in preventing thromboembolic events, but is simultaneously burdened by a narrow therapeutic window, multiple food and drug interactions, and a substantial bleeding risk. New pharmacological agents show only a modest reduction of bleeding complications compared to warfarin. Percutaneous device left atrial appendage (LAA) closure has now been technologically advanced as an additional and potential alternative to pharmacotherapy in patients with AF. Promising randomized data are obtainable with the WATCHMAN® device, while several other devices are in various stages of clinical and preclinical development. In this article we review the current knowledge and status of this technique.

top of page

Publication History

Cite this article as

Corresponding author e-mail

s.moebius@asklepios.com